Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
Aged
Cell Membrane
/ metabolism
Cell Proliferation
/ genetics
Cytoplasm
/ metabolism
Gene Deletion
Humans
Male
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness
Neoplasm Recurrence, Local
/ pathology
Oncogene Proteins, Fusion
/ metabolism
Phenotype
Proportional Hazards Models
Prostate
/ metabolism
Prostatic Neoplasms
/ metabolism
Syndecan-1
/ metabolism
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
04
2020
revised:
27
09
2020
accepted:
30
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
8
5
2021
Statut:
epublish
Résumé
Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in various normal and malignant tissues. It is of interest due to a possible prognostic effect in tumors and its role as a target for the antibody-drug conjugate indatuximab ravtansine. Here, we analyzed 17,747 prostate cancers by immunohistochemistry. Membranous and cytoplasmic CD138 staining was separately recorded. In normal prostate glands, CD138 staining was limited to basal cells. In cancers, membranous CD138 positivity was seen in 19.6% and cytoplasmic CD138 staining in 11.2% of 12,851 interpretable cases. A comparison with clinico-pathological features showed that cytoplasmic CD138 staining was more linked to unfavorable tumor features than membranous staining. Cytoplasmic CD138 immunostaining was associated with high tumor stage (
Identifiants
pubmed: 33195694
doi: 10.1155/2020/5845374
pmc: PMC7641694
doi:
Substances chimiques
Oncogene Proteins, Fusion
0
Syndecan-1
0
TMPRSS2-ERG fusion protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5845374Informations de copyright
Copyright © 2020 Simon Kind et al.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
Int J Oncol. 2012 Jan;40(1):261-8
pubmed: 21956230
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
Carcinogenesis. 2017 Dec 7;38(12):1180-1187
pubmed: 29029032
Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):304-10
pubmed: 16280658
Prostate. 2003 Apr 1;55(1):20-9
pubmed: 12640657
Development. 2017 Jul 1;144(13):2428-2444
pubmed: 28536097
J Biol Chem. 2008 Dec 19;283(51):35435-44
pubmed: 18957427
J Pathol. 2013 Sep;231(1):130-41
pubmed: 23794398
Mol Carcinog. 2016 Sep;55(9):1378-86
pubmed: 26259043
Cancer Res. 2013 May 1;73(9):2795-805
pubmed: 23492366
Prostate. 2017 May;77(13):1312-1324
pubmed: 28744948
Nat Rev Urol. 2012 Feb 21;9(4):196-206
pubmed: 22349653
Ann Oncol. 2005 Jul;16(7):1109-15
pubmed: 15851381
BJU Int. 2010 Aug;106(3):418-23
pubmed: 20002675
Eur J Cancer. 2004 Jun;40(9):1373-82
pubmed: 15177497
Prostate. 2011 Feb 15;71(3):281-8
pubmed: 20809553
Int J Cancer. 2005 Feb 10;113(4):619-28
pubmed: 15472903
ISRN Oncol. 2013 Apr 18;2013:680136
pubmed: 23691363
Int J Oncol. 2014 Mar;44(3):647-54
pubmed: 24424718
Genes Chromosomes Cancer. 2018 Oct;57(10):504-512
pubmed: 29923647
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
J Hematol Oncol. 2017 Jan 11;10(1):13
pubmed: 28077160
BMC Cancer. 2011 Dec 05;11:507
pubmed: 22142399
Mol Carcinog. 2019 Dec;58(12):2306-2315
pubmed: 31545001
Indian J Cancer. 2017 Jul-Sep;54(3):566-571
pubmed: 29798960
APMIS. 2004 Feb;112(2):89-97
pubmed: 15056224
Asian J Androl. 2011 May;13(3):476-80
pubmed: 21317913
BJU Int. 2008 Jan;101(2):232-7
pubmed: 17868422
N Engl J Med. 2011 May 5;364(18):1708-17
pubmed: 21542742
Pharm Res. 2018 Apr 17;35(6):118
pubmed: 29666962
Histol Histopathol. 2014 Feb;29(2):177-89
pubmed: 24150912
J Cell Biol. 2000 Feb 21;148(4):811-24
pubmed: 10684261
Oncotarget. 2016 Dec 27;7(52):86339-86349
pubmed: 27861151
Prostate. 2016 Aug;76(11):977-85
pubmed: 27062540
Sci Rep. 2018 Aug 27;8(1):12868
pubmed: 30150711
Oncotarget. 2015 Sep 29;6(29):27966-79
pubmed: 26293672
Eur Urol. 2012 May;61(5):1019-24
pubmed: 22336380
Mod Pathol. 2008 Nov;21(11):1371-8
pubmed: 18552821
N Engl J Med. 2017 Jul 13;377(2):132-142
pubmed: 28700844
Int J Cancer. 2014 Sep 15;135(6):1369-80
pubmed: 24523142
Oncology. 2005;68(2-3):97-106
pubmed: 15886501
Urology. 2004 Feb;63(2):402-7
pubmed: 14972511
BMC Cancer. 2018 May 31;18(1):612
pubmed: 29855276
Oncotarget. 2017 Nov 11;8(65):108923-108935
pubmed: 29312579
Cell Commun Signal. 2015 Feb 19;13:12
pubmed: 25885538
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Urol Oncol. 2010 Sep-Oct;28(5):534-40
pubmed: 19450993
Histopathology. 2013 Jan;62(2):247-56
pubmed: 23240715
Oncotarget. 2017 Jan 3;8(1):379-392
pubmed: 27880722
Mod Pathol. 2013 Jul;26(7):975-83
pubmed: 23370768
J Pathol. 2013 Dec;231(4):495-504
pubmed: 24549646
J Clin Oncol. 2015 Jan 20;33(3):272-7
pubmed: 25512465
Oncol Rep. 2010 Apr;23(4):917-25
pubmed: 20204274
N Biotechnol. 2018 Oct 25;45:9-13
pubmed: 29355666